[Chinese expert consensus on diagnosis and treatment of pulmonary nodules(2024)].

Lung cancer is the leading cause of the incidence and mortality of malignant tumors in China. The 5-year survival rate released for China in 2018 was 19.7%. The 5-year survival rate for stage Ⅰ patients is 77%-92%. Early diagnosis and treatment of lung cancer are key to improving the 5-year overall survival rate and prognosis of lung cancer patients. Therefore, experts from the Academic Group of Lung Cancer in Chinese Thoracic Society and Chinese Alliance Against Lung Cancer Expert Group formulated the <i>Chinese Expert Consensus on the Diagnosis and Treatment of Lung Nodules</i> in 2015 to standardize the diagnosis and treatment of lung nodules. In 2018, this consensus was updated to formulate the <i>Chinese Expert Consensus on Diagnosis and Treatment of Lung Nodules (2018 edition)</i>, and widely applied in multiple branch centers of Chinese Alliance Against Lung Cancer, proposing the <i>Intelligent Treatment of Million Early Lung Cancer Project</i>. Based on applied experience of the expert consensus in recent years, with reference to the latest evidence has been updated, <i>Chinese Expert Consensus on Diagnosis and Treatment of Lung Nodules (2024 edition)</i> was formulated. The updated content of this consensus mainly includes the following aspects: (1) Define the screening age of high-risk lung cancer populations in China based on the national conditions; (2) Propose definition of "difficult-to-determine pulmonary nodules" to avoid delaying the diagnosis and treatment; (3) Evaluate pulmonary nodules assisted by artificial intelligence (AI) imaging-assisted diagnostic system and propose human-machine MDT to avoid the limitations of AI; (4) Evaluate pulmonary nodules by routine and individualized evaluations for different populations, and make recommendations based on evidence-based management guidelines for different types and sizes of pulmonary nodules. In the updated consensus, 18 consensus points were recommended as a reference for clinical management of pulmonary nodules to improve the 5-year overall survival rate and the prognosis of lung cancer in China.